Favipiravir

In the clinical treatment of respiratory RNA virus infections, the research and development of broad-spectrum antiviral drugs has always been a key direction in the field of public health. Favipiravir is a representative drug of RNA-dependent RNA polymerase (RdRp) inhibitors in this category. It selectively inhibits the activity of viral RdRp and blocks the replication and transcription process of the viral genome, showing a definite inhibitory effect on a variety of RNA viruses. At present, this drug is mainly used clinically for the treatment of new or recurrent influenza in adults, and has also been included in the diagnosis and treatment plan for novel coronavirus infection, applicable to adult patients without contraindications, providing more options for the clinical intervention of RNA virus infectious diseases.

The global market size of favipiravir exceeded 2.8 billion yuan at its peak during the public health event in 2020. With the adjustment of epidemic prevention and control policies later, the market size has declined to some extent. However, due to its rigid demand attribute in influenza prevention and control, it has maintained a compound annual growth rate of about 5% in recent years. The domestic market is currently dominated by generic drug supplies. Leading API enterprises in Zhejiang, Shandong and other regions account for nearly 70% of the domestic API supply share. After the implementation of centralized procurement, the terminal price of preparations has dropped by more than 80%, and the accessibility for patients has been greatly improved.

The original research enterprise of favipiravir is Toyama Chemical Co., Ltd. of Japan, and the original research trade name is Avigan®. The expiration date of its core compound patent in Japan is 2031. Since the compound patent in China has been declared invalid, domestic enterprises can legally produce generic APIs and preparations. The original research dosage form is tablet, with two specifications of 200mg and 400mg. The original research product has been included in the Japanese Orange Book reference preparation catalogue, and has not been imported and marketed in China. At present, 13 domestic enterprises have completed the registration of favipiravir APIs with CDE, and another 8 generic drug preparations have been approved for marketing for clinical use. (Data as of October 2024, please refer to the official CDE website for the latest information)

CATO can provide a full series of favipiravir impurity reference standards. Most products are in sufficient stock. In-stock products ordered before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and fully meet the reference standard use needs of API enterprises in various stages such as R&D, quality research, and registration and declaration.